Yahong Pharmaceuticals accumulated revenue of 0.139 billion yuan in the first three quarters of this year, with two commercialized products continuing to ramp up production.

Gelonghui Finance · Oct 29 05:55

On the evening of October 29, Yahong Pharmaceutical (688176.SH) disclosed its three-quarter report. In the third quarter, the company achieved revenue of 58.4582 million yuan, an increase of 1903.16% over the previous year; in the first three quarters, the cumulative revenue was 0.139 billion yuan, an increase of 4537.79% over the previous year. The increase in revenue was mainly due to the company's start selling prazopanib tablets (trade name: Dipate) and neratinib maleate tablets (trade name: Ourobi) in the fourth quarter of 2023. Commercialization progressed steadily during the reporting period, and sales increased.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

亚虹医药今年前三季度累计营收1.39亿元 两款商业化产品持续放量

Yahong Pharmaceuticals accumulated revenue of 0.139 billion yuan in the first three quarters of this year, with two commercialized products continuing to ramp up production.

Risk Disclaimer

Statement

亚虹医药今年前三季度累计营收1.39亿元两款商业化产品持续放量